Enantiomerically pure 1,4-benzodiazepine-2,5-diones as Hdm2 antagonists
Juan Marugán(National Institutes of Health), Tianbao Lu(Johnson & Johnson (United States)), Maxwell D. Cummings(Johnson & Johnson (United States)), Mark R. Player(Johnson & Johnson (United States)), Pierre Raboisson(Johnson & Johnson (United States)), Anna C. Maroney(AbbVie (United States)), Raul R. Calvo(Johnson & Johnson (United States)), Joan M. Gushue(Johnson & Johnson (United States)), Kristi Leonard(Johnson & Johnson (United States)), Carsten J. Schubert(Johnson & Johnson (United States)), Jennifer Lattanze(Johnson & Johnson (United States)), Shuyuan Zhao(Johnson & Johnson (United States)), Holly K. Koblish(Wilmington University)
Cited by 34
Related Papers
Discovery and Cocrystal Structure of Benzodiazepinedione HDM2 Antagonists That Activate p53 in Cells
|Journal of Medicinal Chemistry|2005|430
Motoneuron Apoptosis Is Blocked by CEP-1347 (KT 7515), a Novel Inhibitor of the JNK Signaling Pathway
|Journal of Neuroscience|1998|293
The MLK Family Mediates c-Jun N-Terminal Kinase Activation in Neuronal Apoptosis
|Molecular and Cellular Biology|2001|268
beta-Amyloid-induced neuronal apoptosis requires c-Jun N-terminal kinase activation
|Journal of Neurochemistry|2001|223